PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 186 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2014. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $12,636 | +26.4% | 3,912 | +10.1% | 0.00% | – |
Q1 2022 | $10,000 | -9.1% | 3,554 | 0.0% | 0.00% | – |
Q4 2021 | $11,000 | -86.9% | 3,554 | -70.4% | 0.00% | – |
Q3 2021 | $84,000 | +50.0% | 12,012 | +98.7% | 0.00% | – |
Q2 2021 | $56,000 | -5.1% | 6,045 | 0.0% | 0.00% | – |
Q1 2021 | $59,000 | -7.8% | 6,045 | -2.5% | 0.00% | – |
Q4 2020 | $64,000 | +3.2% | 6,203 | 0.0% | 0.00% | – |
Q3 2020 | $62,000 | -22.5% | 6,203 | -19.2% | 0.00% | – |
Q2 2020 | $80,000 | +25.0% | 7,681 | +1.3% | 0.00% | – |
Q1 2020 | $64,000 | -17.9% | 7,584 | -15.2% | 0.00% | – |
Q4 2019 | $78,000 | -7.1% | 8,945 | +15.1% | 0.00% | – |
Q3 2019 | $84,000 | -58.0% | 7,773 | -50.5% | 0.00% | – |
Q2 2019 | $200,000 | -64.9% | 15,712 | +7.2% | 0.00% | – |
Q1 2019 | $569,000 | +90.3% | 14,657 | 0.0% | 0.00% | – |
Q4 2018 | $299,000 | -34.7% | 14,657 | +46.8% | 0.00% | – |
Q3 2018 | $458,000 | -24.3% | 9,981 | -2.4% | 0.00% | – |
Q2 2018 | $605,000 | -17.2% | 10,226 | -4.8% | 0.00% | -100.0% |
Q1 2018 | $731,000 | -41.8% | 10,744 | -15.3% | 0.00% | 0.0% |
Q4 2017 | $1,256,000 | -11.0% | 12,688 | +6.9% | 0.00% | 0.0% |
Q3 2017 | $1,411,000 | +53.7% | 11,865 | +13.1% | 0.00% | 0.0% |
Q2 2017 | $918,000 | +165.3% | 10,490 | +12.8% | 0.00% | – |
Q1 2017 | $346,000 | +24.9% | 9,297 | +2.8% | 0.00% | – |
Q4 2016 | $277,000 | -27.5% | 9,048 | +51.7% | 0.00% | – |
Q3 2016 | $382,000 | +108.7% | 5,963 | -2.9% | 0.00% | – |
Q2 2016 | $183,000 | +144.0% | 6,142 | +142.4% | 0.00% | – |
Q1 2016 | $75,000 | -23.5% | 2,534 | +102.4% | 0.00% | – |
Q4 2015 | $98,000 | -90.1% | 1,252 | -90.5% | 0.00% | -100.0% |
Q3 2015 | $990,000 | +8.8% | 13,142 | +68.7% | 0.00% | 0.0% |
Q2 2015 | $910,000 | -5.9% | 7,791 | +89.3% | 0.00% | 0.0% |
Q1 2015 | $967,000 | +48.3% | 4,116 | +19.8% | 0.00% | 0.0% |
Q4 2014 | $652,000 | -25.6% | 3,435 | -4.2% | 0.00% | 0.0% |
Q3 2014 | $876,000 | – | 3,584 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |